Abeona Therapeutics develops cell and gene therapies, led by ZEVASKYN, a treatment for skin wounds caused by a rare inherited skin disease. ABEO reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for ABEO are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in ABEO in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABEO is in one of them and how their past ABEO trades turned out.
Abeona Therapeutics is a biopharmaceutical company based in Cleveland, Ohio, that develops cell and gene therapies for rare genetic diseases. Its main product, ZEVASKYN, treats skin wounds in patients with recessive dystrophic epidermolysis bullosa, a rare inherited skin disease. The treatment uses a patient's own skin cells, which are modified and applied surgically at specialized treatment centers. Its pipeline also includes gene therapies for eye diseases.
